Is it all the RAGE? Defining the role of the receptor for advanced glycation end products in Parkinson's disease
- PMID: 37381043
- DOI: 10.1111/jnc.15890
Is it all the RAGE? Defining the role of the receptor for advanced glycation end products in Parkinson's disease
Abstract
The receptor for advanced glycation end products (RAGE) is a transmembrane receptor that belongs to the immunoglobulin superfamily and is extensively associated with chronic inflammation in non-transmissible diseases. As chronic inflammation is consistently present in neurodegenerative diseases, it was largely assumed that RAGE could act as a critical modulator of neuroinflammation in Parkinson's disease (PD), similar to what was reported for Alzheimer's disease (AD), where RAGE is postulated to mediate pro-inflammatory signaling in microglia by binding to amyloid-β peptide. However, accumulating evidence from studies of RAGE in PD models suggests a less obvious scenario. Here, we review physiological aspects of RAGE and address the current questions about the potential involvement of this receptor in the cellular events that may be critical for the development and progression of PD, exploring possible mechanisms beyond the classical view of the microglial activation/neuroinflammation/neurodegeneration axis that is widely assumed to be the general mechanism of RAGE action in the adult brain.
Keywords: Parkinson's disease; RAGE; dopaminergic neurodegeneration; neuroinflammation; α‐Synuclein.
© 2023 International Society for Neurochemistry.
References
REFERENCES
-
- Abdelsalam, R. M., & Safar, M. M. (2015). Neuroprotective effects of vildagliptin in rat rotenone Parkinson‘s disease model: Role of RAGE‐NFκB and Nrf2‐antioxidant signaling pathways. Journal of Neurochemistry, 133(5), 700–707. https://doi.org/10.1111/jnc.13087
-
- Abe, R., Shimizu, T., Sugawara, H., Watanabe, H., Nakamura, H., Choei, H., Sasaki, N., Yamagishi, S., Takeuchi, M., & Shimizu, H. (2004). Regulation of human melanoma growth and metastasis by AGE‐AGE receptor interactions. The Journal of Investigative Dermatology, 122(2), 461–467. https://doi.org/10.1046/j.0022‐202X.2004.22218.x
-
- Arumugam, T., Ramachandran, V., Gomez, S. B., Schmidt, A. M., & Logsdon, C. D. (2012). S100P‐derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clinical Cancer Research, 18(16), 4356–4364. https://doi.org/10.1158/1078‐0432.CCR‐12‐0221
-
- Azar, Y. O., Badawi, G. A., Zaki, H. F., & Ibrahim, S. M. (2022). Agmatine‐mediated inhibition of NMDA receptor expression and amelioration of dyskinesia via activation of Nrf2 and suppression of HMGB1/RAGE/TLR4/MYD88/NF‐κB signaling cascade in rotenone lesioned rats. Life Sciences, 311(Pt A, 121049. https://doi.org/10.1016/j.lfs.2022.121049
-
- Barocio‐Pantoja, M., Quezada‐Fernández, P., Cardona‐Müller, D., Jiménez‐Cázarez, M. B., Larios‐Cárdenas, M., González‐Radillo, O. I., García‐Sánchez, A., Carmona‐Huerta, J., Chávez‐Guzmán, A. N., Díaz‐Preciado, P. A., Balleza‐Alejandri, R., Pascoe‐González, S., & Grover‐Páez, F. (2021). Green tea extract increases soluble RAGE and improves renal function in patients with diabetic nephropathy. Journal of Medicinal Food, 24(12), 1264–1270. https://doi.org/10.1089/jmf.2020.0212
Publication types
MeSH terms
Substances
Grants and funding
- 88881.512990/2020-01/Alexander von Humboldt-Stiftung
- 301175/2019-5/Conselho Nacional de Desenvolvimento Científico e Tecnológico
- 408435/2018-6/Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- EXC 2067/1- 390729940/Deutsche Forschungsgemeinschaft
LinkOut - more resources
Full Text Sources
Medical
Research Materials